Manufacturer And Supplier Anti Obesity GLP-1 Weight Loss CAS 2023788-19-2

is an advanced pharmaceutical compound developed by Eli Lilly and Company. It is classified as a dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual action makes effective in managing type 2 diabetes and has shown significant promise in promoting weight loss. Marketed under the brand name , has garnered attention for its efficacy and innovative mechanism of action.

Peptide Powder Explained peptide powder refers to the raw, unprocessed form of the molecule. As a peptide, it consists of a specific sequence of amino acids that enable it to interact with the GIP and GLP-1 receptors in the body. The powder form is typically intended for research purposes, pharmaceutical manufacturing, or compounding into injectable solutions under controlled conditions.

1. Medical Treatment: In its approved form (e.g., ), is used to improve blood sugar control in adults with type 2 diabetes. Its dual agonist properties help enhance insulin secretion, reduce glucagon levels, and slow gastric emptying, contributing to better glycemic management.
2. Weight Management: Clinical trials have demonstrated 's effectiveness in promoting significant weight loss, making it a potential option for individuals struggling with obesity or those at risk of weight-related health issues.
3. Research and Development: peptide powder is valuable for scientific studies exploring its pharmacodynamics, pharmacokinetics, and potential new therapeutic applications.